WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Series C

Endogenex adds $50M Series C extension to finish the ReCET diabetes study

MedDevice Startups Staff · Mar 25 · 2 min read · Via MassDevice

Endogenex closed a $50M extension to its Series C on March 25, 2026. Arboretum Ventures led as a new investor, and existing Series C investors participated. With the $88M first close in June 2024, the Series C now totals $138M.

ReCET is an endoscopic catheter procedure. It applies non-thermal pulsed electric fields to the duodenal lining in adults with type 2 diabetes whose glucose is not controlled. FDA granted Breakthrough Device designation and approved the IDE in November 2023. The ReCET Clinical Study is randomized, double-blinded and sham-controlled, with sites in the US and Australia.

CEO Stacey Pugh said the funding takes the company through the study and through FDA approval. The company has not disclosed an enrollment count or a submission date. A sham-controlled endoscopic trial with a PMA at the end is expensive to run, which is why a $138M Series C exists.

Questions & Answers

How much did Endogenex raise in its Series C extension?

Endogenex closed a $50M Series C extension on March 25, 2026, led by new investor Arboretum Ventures, bringing the full Series C to $138M.

What is the Endogenex ReCET System?

ReCET is an endoscopic catheter treatment that applies non-thermal pulsed electric fields to the duodenal lining in adults with inadequately controlled type 2 diabetes.

Does Endogenex ReCET have FDA Breakthrough Device designation?

Yes. FDA granted ReCET Breakthrough Device designation and approved its IDE in November 2023; the randomized, sham-controlled ReCET Clinical Study is enrolling in the US and Australia.

← Back to Fundraising